China's WuXi AppTech falls on US House bill curbing genetic info sharing

AviChina Industry & Technology Co

29/01/2024 03:34

** Hong Kong shares of Chinese new drug research and
development group WuXi AppTech  2359.GHK  fall 6.2% to HK$60.60
in their fourth consecutive session of decline
    ** Stock top loser in the Hang Seng Index  .HSI  and Hang
Seng Commerce & Industry Index  .HSNC ; on track to end the
month down 23.2%, marking its biggest monthly decline since
September 2022
    ** Its Shanghai stock  603259.SS  down 10% 
    ** A congressional committee focused on China has introduced
a bill that would restrict federally funded medical providers
from allowing China's BGI Group, WuXi AppTec and other biotech
companies from getting genetic information about Americans 
    ** WuXi AppTec said on Friday that its business development
will not pose any security risk for any country
    ** WuXi Biologics  2269.HK  also says its CEO Zhisheng Chen
has neither worked for the Academy of Military Medical Sciences
or any military-affiliated institution, nor has he received
compensation from military-affiliated institutions
    ** Shares of WuXi Biologics  2269.HK  drop 4.5% 
    ** Hang Seng Commerce & Industry Index  .HSNC  and Hang Seng
Index  .HSI  both rise 1.4%
    

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))